- Poster presentation
- Open Access
Development of a novel simian adenovirus 24 based vaccine vector
Retrovirology volume 9, Article number: P309 (2012)
Human adenovirus serotype 5 is a potent vaccine vector, but its use has been hampered by high seroprevalence amongst people in sub-Sahara Africa. Novel adenoviral vaccine vectors from strains with lower seroprevalence worldwide are being developed that can evade pre-existing immunity. Here we describe the development of a simian Ad24 (sAd24)-based vaccine vector.
Neutralizing antibodies against sAd24 were determined using a panel of 106 rhesus macaque sera and 128 human sera from Rwanda and South Africa using a luciferase-based adenovirus neutralization assay.
The immunogenicity of a single dose of 10E7, 10E8 or 10E9 virus particles of sAd24-SIV Gag based vector was determined in C57BL/6 mice. SIV-Gag-specific immune responses were assessed by Db/AL11 tetramer binding assays, IFN-γ ELISPOT assays and ICS assays.
Neutralizing antibodies were found in 7% of monkeys, all with titers <200. In humans from sub-Saharan Africa, 45% was positive for sAd24 neutralizing antibodies, but titers remained low and 90% had titers <200. In comparison, seroprevalence of Ad5 in sub-Saharan Africa is 86.4-89.5% with 61.1-78.7% of this population showing titers >200 and 25.1-46.8% showing titers >1000. Gag specific cellular immune responses elicited by sAd24-SIV Gag in mice are comparable to those seen with the human Ad26 and Ad28 vectors currently in development.
These data suggest that sAd24 is promising for further studies as a candidate vaccine vector.
About this article
Cite this article
Abbink, P., Bradley, R., Ball, F. et al. Development of a novel simian adenovirus 24 based vaccine vector. Retrovirology 9, P309 (2012) doi:10.1186/1742-4690-9-S2-P309
- ELISPOT Assay
- Neutralization Assay
- High Seroprevalence
- Human Adenovirus
- Vaccine Vector